Liposomal formulations for inhalation

Therapeutic Delivery

Volumn 4, Issue 8, 2013, Pages 1047-1072

  Cipolla, David ^a,b   Gonda, Igor ^b   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ARADIGM CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ARIKACE; BECLOMETASONE; CIPROFLOXACIN; CISPLATIN; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; FENTANYL; ILOPROST; INTERLEUKIN 2; LIPOSOME; PULMAQUIN; RUBITECAN; SALBUTAMOL SULFATE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

AEROSOL; COLONY FORMING UNIT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY POWDER; ENCAPSULATION; HUMAN; INHALER; NEBULIZATION; NEBULIZER; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84881539706     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.71     Document Type: Review

References (129)

1. Allen TM. Pharmacokinetics and biopharmaceutics of lipid-based drug formulations. In: Liposome Technology, Third Edition. Gregoriadis G (Ed.). Informa Healthcare, NY, USA, 49-64 (2007).
2. Jain NK, Mishra V, Mehra NK. Targeted drug delivery to macrophages. Expert Opin. Drug Deliv. 10(3), 353-367 (2013).
3. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampicin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection in mice. Antimicrob. Agents Chemother. 41(6) 1211-1214 (1997).
4. Mihalko PJ, Schreier H, Abra RM. Liposomes: a pulmonary perspective. In: Liposomes as Drug Carriers. Gregoriadis G (Ed.). John Wiley and Sons, NJ, USA, 679-694 (1988).
5. Abra, RM, Hunt CA, Lau DT. Liposome disposition in vivo. VI: delivery to the lung. J. Pharm. Sci. 73(2), 203-206 (1984).
6. Schreier H, Gonzalez-Rothi RJ, Stecenko AA. Pulmonary delivery of liposomes. J. Control. Release 24(1-3), 209-223 (1993).
7. Chowdhary RK, Shariff I, Dolphin D. Drug release characteristics of lipid based benzoporphyrin derivative. J. Pharm. Pharm. Sci. 6(1), 13-19 (2003).
8. Cipolla D, Redelmeier T, Eastman S, Bruinenberg P, Gonda I. Liposomes, niosomes and proniosomes - a critical update of their (commercial) development as inhaled products. In: Respiratory Drug Delivery Europe 2011. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, IL, USA, 41-54 (2011).
9. Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Microaerosol administration of synthetic beta-gamma-diapalmitoyl-l-alpha- lecithin in the respiratory distress syndrome: a preliminary report. Can. Med. Assoc. J. 90, 55-57 (1964).
10. Ivey HH, Roth S, Kattwinkel J. Use of nebulized surfactants in treatment of the respiratory distress syndrome (RDS) of infancy. Pediatr. Res. 462 Abstract 964 (1976).
11. Ivey HH, Roth S, Kattwinkel J. Nebulization of sonicated phospholipids for treatment of respiratory distress syndrome (RDS) of infancy. Pediatr. Res. 573 Abstract 1207 (1977).
12. McCullough HN, Juliano RL. Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat. J. Natl Cancer Inst. 63(3), 727-731 (1979).
13. Juliano RL, McCullough HN. Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system. J. Pharmacol. Exp. Ther. 214(2), 381-387 (1980).
14. Taylor KM, Taylor G, Kellaway IW, Stevens J. The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm. Res. 6(7), 633-636 (1989).
15. Waldrep JC, Keyhani K, Black M, Knight V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 105(1), 106-110 (1994).
16. Pettenazzo A. Jobe A, Ikegami M et al. Clearance of phosphatidylcholine and cholesterol from liposomes, liposomes loaded with metaproterenol, and rabbit surfactant from adult rabbit lungs. Am. Rev. Respir. Dis. 139(3), 752-758 (1989).
17. Fielding RM, Abra RM. Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm. Res. 9(2), 220-223 (1992).
18. Abra RM, Mihalko PJ, Schreier H. The effect of lipid composition upon the encapsulation and in vitro leakage of metaproterenol sulfate from 0.2 ?m diameter, extruded, multilamellar liposomes. J. Control. Release 14(1), 71-78 (1990).
19. Wittgen BP, Kunst PW, Perkins WR et al. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J. Aerosol Med. 19(3), 385-391 (2006).
20. Weers J, Metzheiser B, Taylor G et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J. Aerosol Med. Pulm. Drug Deliv. 22(2), 131-138 (2009).
21. Serisier DJ, Bilton D, De Soyza A et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax doi:10.1136/thoraxjnl-2013-203207 (Epub ahead of print) (2013).
22. Bruinenberg P, Blanchard JD, Cipolla DC, Dayton F, Mudumba S, Gonda I. Inhaled liposomal ciprofloxacin: once a day management of respiratory infections. In: Respiratory Drug Delivery 2010. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, IL, USA, 73-81 (2010).
23. Bruinenberg P, Otulana B, Blanchard J, Cipolla D, Wilson J, Serisier D. Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in CF patients. Presented at: 32nd European Cystic Fibrosis Conference, Brest, France, 11 June 2009.
24. Bilton D, DeSoyza A, Haworth C, Bruinenberg P, Otulana B. Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in non-CF bronchiectasis. Presented at: ERS Annual Conference, Abstract 1362, Vienna, Austria, 13 September 2009.
25. Farr SJ, Kellaway IW, Parry-Jones DR, Woolfrey SG. 99m-Technetium as a marker of liposomal deposition and clearance in the human lung. Int. J. Pharm. 26(3), 303-316 (1985).
26. Barker SA, Taylor KMG, Short MD. The deposition and clearance of liposome entrapped 99mTc-DTPA in the human respiratory tract. Int. J. Pharm. 102(1-3), 159-165 (1994).
27. Thomas DQ, Myers MA, Wichert B, Schreier H, Gonzalez-Rothi RJ. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 99(5), 1268-1270 (1991).
28. Waldrep JC, Gilbert BE, Knight CM et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest 111(2), 316-323 (1997).
29. Saari SM, Vidgren MT, Koskinen MO, Turjanmaa VM, Waldrep JC, Nieminen MM. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 113(6), 1573-1579 (1998).
30. Saari M, Vidgren MT, Koskinen MO, Turjanmaa VM, Nieminen MM. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int. J. Pharm. 181(1), 1-9 (1999).
31. Saari SM, Vidgren MT, Herrala J, Koshkinen MO, Nieminen MM. Possibilities of formoterol to enhance the peripheral lung deposition of the inhaled liposome corticosteroids. Respir. Med. 96(12), 999-1005 (2002).
32. Verschraegen CF, Gilbert BE, Huaringa AJ et al. Feasibility, Phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)- camptothecin in patients with advanced malignancies in the lungs. Ann. NY Acad. Sci. 922, 352-354 (2000).
33. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a Phase I clinical trial. Anticancer Drugs 11(7), 555-563 (2000).
34. Hung OR, Sellers EM, Kaplan HL, Romach MK. Phase 1B clinical trial of aeroslized liposome encapsulated fentanyl (Aerolef). Clin. Pharmacol. Ther. Abstract PI-3 (2004).
35. Gilbert BE, Knight C, Alvarez FG et al. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am. J. Respir. Crit. Care Med. 156(6), 1789-1793 (1997).
36. Behr J, Zimmermann G, Baumgartner R et al. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J. Aerosol Med. Pulm. Drug Deliv. 22(2), 121-130 (2009).
37. Slobbe L, Boersma E, Rijnders BJ. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm. Pharmacol. Ther. 21(6), 855-859 (2008).
38. Monforte V, Ussetti P, Lopez R et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J. Heart Lung Transplant. 28(2), 170-175 (2009).
39. Monforte V, Ussetti P, Gavalda J et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J. Heart Lung Transplant. 29(5), 523-530 (2010).
40. Monforte V, Lopez-Sanchez A, Zurbano F et al. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J. Lung Transplant. 32(3), 313-319 (2013).
41. Okusanya OO, Bhavnani SM, Hammel J et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 53(9), 3847-3854 (2009).
42. O'Donnell A, Swarnakar L, Yashina et al. A placebo controlled study of liposomal amikacin for inhalation (ARIKACE™) nebulized once-daily in the treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa lung infection. Presented at: ERS Annual Conference Abstract 1361, Vienna, Austria, 13 September 2009.
43. Clancy JP, Minic P, Dupont L et al. Full analyses of data from two Phase II blinded and placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Pediatr. Pulm. 299 Abstract 227 (2010).
44. Bruinenberg P, Otulana B, Blanchard J et al. The effect of once-a-day, inhaled liposomal ciprofloxacin hydrochloride for inhalation on bacterial density in cystic fibrosis patients with P. aeruginosa infection. Pediatr. Pulm. 43(Suppl. 31), 401 (2008).
45. Bruinenberg P, Serisier D, Blanchard J, Cipolla D, Gonda I. Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. Presented at: ERS Annual Conference Abstract 5574, Barcelona, Spain, 22 September 2010.
46. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56(5), 747-756 (1998).
47. Cipolla D, Chan H-K, Schuster J, Farina D. Personalizing aerosol medicine: development of delivery systems tailored to the individual. Ther. Deliv. 1(5), 667-682 (2010).
48. Taylor KMG, Taylor G, Kellaway IW, Stevens J. The stability of liposomes to nebulisation. Int. J. Pharm. 58(1), 57-61 (1990).
49. Kellaway IW, Farr SJ. Liposomes as drug delivery systems to the lung. Adv. Drug Del. Rev. 5(1-2), 149-161 (1990).
50. Niven RW, Schreier H. Nebulization of liposomes. I. Effects of lipid composition. Pharm. Res. 7(11), 1127-1133 (1990).
51. Niven RW, Speer M, Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm. Res. 8(2), 217-221 (1991).
52. Taylor KM, Newton JM. Liposomes for controlled delivery of drugs to the lung. Thorax 47(4), 257-259 (1992).
53. Niven RW, Carvajal TM, Schreier H. Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm. Res. 9(4), 515-520 (1992).
54. Taylor KMG, Farr SJ, Liposomes for drug delivery to the respiratory tract. Drug Dev. Ind. Pharm. 19(1&2), 123-142 (1993).
55. Cipolla DC, Gonda I. Formulation technology to repurpose drugs for inhalation delivery. Drug Discov. Today Ther. Strateg. 8(3-4) 123-130 (2011).
56. Shek PN, Suntres ZE, Brooks JI. Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery. J. Drug Target. 2(5), 431-442 (1994).
57. Cipolla D, Wu H, Chan J, Chan H-K, Gonda I. Liposomal ciprofloxacin for inhalation retains integrity following nebulization. In: Respiratory Drug Delivery Europe 2013. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, IL, USA, 237-242 (2013).
58. Cipolla DC, Dayton F, Fulzele S et al. Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance. In: Respiratory Drug Delivery 2010. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, IL, USA, 409-414 (2010).
59. Gilbert BE, Six HR, Wilson SZ, Wyde PR, Knight V. Small particle aerosols of enviroxime-containing liposomes. Antiviral Res. 9(6), 355-365 (1988).
60. Bridges PA, Taylor KMG. Nebulisers for the generation of liposomal aerosols. Int. J. Pharm. 173(1-2), 117-125 (1998).
61. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol. 44(3), 177-186 (1999).
62. Saari M, Vidgren MT, Koshkinen MO, Turjanmaa VM, Nieminen MM. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int. J. Pharm. 181(1), 1-9 (1999).
63. Koshkina NV, Knight V, Gilbert BE, Golunski E, Roberts L, Waldrep JC. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2- enriched air: pharmacokinetic studies. Cancer Chemother. Pharmacol. 47(5), 451-456 (2001).
64. Elhissi AM, Karnam KK, Danesh-Azari MR, Gill HS, Taylor KM. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers. J. Pharm. Pharmacol. 58(7), 887-894 (2006).
65. Parthasarathy R, Mehta K. Altered metabolism of all-trans-retinoic acid in liposome-encapsulated form. Cancer Lett. 134(2), 121-128 (1998).
66. Yim D, Blanchard JD, Mudumba S et al. The development of inhaled liposome-encapsulated ciprofloxacin to treat cystic fibrosis. In: Respiratory Drug Delivery 2006. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, IL, USA, 425-428 (2006).
67. Ruijgrok EJ, Vulto AG, Van Etten EW. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in vivo amphotericin B deposition in rats. J. Pharm. Pharmacol. 52(6), 619-627 (2000).
68. Kazantseva M, Craus K, Barry CE, Hickey AJ. Isoxyl (thiocarlide) liposome preparations for aerosol treatment of tuberculosis. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Healthcare International Publishing, IL, USA, 711-713 (2002).
69. Egle R, Bitterle E, Gruber F, Keller M. Characterization of a liposomal ciclosporin A formulation before and after lyophilization and nebulization. Presented at: AAPS National Meeting, AM-08-00983 Atlanta, Georgia, USA, 16-20 November, 2008.
70. Debs RJ, Straubinger RM, Brunette EN et al. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. Am. Rev. Respir. Dis. 135(3), 731-737 (1987).
71. Wichert BV, Gonzalez-Rothi RJ, Straub LE, Wichert BM, Schreier H. Amikacin liposomes: characterization, aerosolization, and in vitro activity against Mycobacterium avium-intracellulare in alveolar macrophages. Int. J. Pharm. 78(1-3), 227-235 (1992).
72. Waldrep JC, Scherer PW, Keyhani K, Knight V. Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition. Int. J. Pharm. 97(1-3), 205-212 (1993).
73. Khanna C, Waldrep JC, Andersen PM et al. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J. Pharm. Pharmacol. 49(10), 960-971 (1997).
74. Finlay WH, Wong JP. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int. J. Pharm. 167(1-2), 121-127 (1998).
75. Knight V, Koshikina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anti cancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenosrafts in nude mice. In: Respiratory Drug Delivery VI. Dalby RN, Byron PR, Farr SJ (Eds). Davis Healthcare International Publishing, IL, USA, 355-358 (1998).
76. Abu-Dahab R, Schafer UF, Lehr CM. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur. J. Pharm. Sci. 14(1), 37-46 (2001).
77. Lange CF, Hancock RE, Samuel J, Finlay WH. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J. Pharm. Sci. 90(10), 1647-1657 (2001).
78. Desai TR, Hancock RE, Finlay WH. A facile method of delivery of liposomes by nebulization. J. Control. Release 84(1-2), 69-78 (2002).
79. Bhavane R, Karathanasis E, Annapragada AV. Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. J. Control. Release 93(1), 15-28 (2003).
80. Tservistas M, Lintz FC, Keller M. Impact of the nebulization principle on the biological activity of labile formulations containing liposomes, peptides and proteins. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman J, Farr SJ (Eds). Davis Healthcare International Publishing, IL, USA, 613-615 (2004).
81. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269(1) 37-49 (2004).
82. Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int. J. Pharm. 296(1-2), 12-25 (2005).
83. Wagner A, Vorauer-Uhl K, Katinger H. Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer. J. Liposome Res. 16(2), 113-125 (2006).
84. Anabousi S, Kleemann E, Bakowsky U et al. Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J. Nanosci. Nanotechnol. 6(9-10), 3010-3016 (2006).
85. Kleemann E, Schmehl T, Gessler T, Bakowsky U, Kissel T, Seeger W. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharm. Res. 24(2) 277-287 (2007).
86. Elhissi AM, Faizi M, Maji WF, Gill HS, Taylor KM. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int. J. Pharm. 334(1-2), 62-70 (2007).
87. Kaipel M, Wagner A, Wassermann E et al. Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. J. Aerosol Med. Pulm. Drug Deliv. 21(3), 281-290 (2008).
88. Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W. Inhalable liposomal formulation for vasoactive intestinal peptide. Int. J. Pharm. 357(1-2), 286-294 (2008).
89. Meers P, Neville M, Malinin V et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 61(4), 859-868 (2008).
90. Gaspar MM, Ehrhardt C. Inf luence of nebulization on physicochemical properties of liposomes. In: Respiratory Drug Delivery 2008. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, IL, USA, 771-774 (2008).
91. Li Z, Zhang Y, Wurtz W et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol Med. Pulm. Drug Deliv. 21(3), 245-254 (2008).
92. Gaspar MM, Gobbo O, Ehrhardt C. Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulizers. J. Liposome Res. 20(1), 55-61 (2010).
93. Elhissi A, Gill H, Ahmed W, Taylor K. Vibrating-mesh nebulization of liposomes generated using an ethanol-based proliposome technology. J. Liposome Res. 21(2), 173-180 (2011).
94. Alexander BD, Winkler TP, Shi S, Dodds Ashley ES, Hickey AJ. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. Pharm. Dev. Technol. 16(6), 577-582 (2011).
95. Elhissi AM, Giebultowicz J, Stec AA et al. Nebulization of ultradeformable liposomes: the inf luence of aerosolization mechanism and formulation excipients. Int. J. Pharm. 436(1-2), 519-526 (2012).
96. Stark B, Debbage P, Andreae F, Mosgoeller W, Prassl R. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim. Biophys. Acta 1768(3), 705-714 (2007).
97. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. Liposomes for drug delivery to the lungs by nebulization. Eur. J. Pharm. Biopharm. 67, 655-666 (2007).
98. Desai TR, Wong JP, Hancock REW, Finlay WH. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J. Pharm Sci. 91(2), 482-491 (2002).
99. Leung KKM, Bridges PA, Taylor KMG. The stability of liposomes to ultrasonic nebulisation. Int. J. Pharm. 145(1-2), 95-102 (1996).
100. Berlinski A, Waldrep C. Effect of aerosol delivery system and formulation on nebulized budesonide output. J. Aerosol Med. 10(4), 307-318 (1997).
101. Pillai R, Petrak K, Blezinger P et al. Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration. Pharm. Res. 15(11), 1743-1747 (1998).
102. Wang WJ, Liao B, Zeng M, Zhu C, Fan XM. The effects of aerosolized STAT1 antisense oligodeoxynucleotides on rat pulmonary fibrosis. Cell. Mol. Immunol. 6(1), 51-59 (2009).
103. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J. Control. Release 113(1), 9-14 (2006).
104. Rottier BL, van Erp CJP, Sluyter TS, Heijerman HGM, Frijilink HW, de Boer AH. Changes in performance of the Pari eFlow Rapid and Pari LC Plus during 6 months use by CF patients. J. Aerosol Med. Pulm. Drug Deliv. 22(3), 263-269 (2009).
105. Elhissi AM, Ahmed W, Taylor KM. Laser diffraction and electron microscopy studies on inhalable liposomes generated from particulate-based proliposomes within a medical nebulizer. J. Nanosci. Nanotechnol. 12(8), 6693-6699 (2012).
106. Deshpande D, Blanchard J, Srinivasan S et al. Aerosolization of lipoplexes using AERx® pulmonary delivery system. AAPS PharmSci. 4(3), 12-21 (2002).
107. Farr SJ, Kellaway IW, Carman-Meakin B. Assessing the potential of aerosol-generated liposomes from pressurised pack formulations. J. Control. Release 5(2), 119-127 (1987).
108. Farr SJ, Kellaway IW, Carman-Meakin B. Comparison of solute partitioning and efflux in liposomes formed by a conventional and an aerosolised method. Int. J. Pharm. 51(1), 39-46 (1989).
109. Venthoye G, Burbridge K, Bond SW, Williams WP, Brain APR. Characterisation of the fine particle fraction from pro-liposome inhalation systems. In: Respiratory Drug Delivery VI. Dalby RN, Byron PR, Farr SJ (Eds). Davis Healthcare International Publishing, IL, USA, 445-447 (1998).
110. Alouache AI, Kellaway IW, Taylor KMG. Pressurised metered dose inhaler solution formulations to generate controlled release colloids. In: Respiratory Drug Delivery 2006. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, IL, USA, 853-856 (2006).
111. Misra A, Jinturkar K, Patel D, Lalani J, Chougle M. Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opin. Drug Deliv. 6(1), 71-89 (2009).
112. Willis L, Hayes D, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 190(3), 251-262 (2012).
113. Ingvarsson PT, Yang M, Nielsen HM, Rantanen J, Foged C. Stabilization of liposomes during drying. Expert Opin. Drug Deliv. 8(3), 375-388 (2011).
114. Sweeney LG, Wang Z, Loebenberg R, Wong JP, Lange CF, Finlay WH. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int. J. Pharm. 305(1-2), 180-185 (2005).
115. Crowe JH, Crowe LM, Carpenter JF, Aurell Wistron C. Stabilization of dry phospholipid bilayers and proteins by sugars. Biochem. J. 242(1), 1-10 (1987).
116. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim. Biophys. Acta 817(1), 67-74 (1985).
117. Strauss G, Schurtenberger P, Hauser H. The interaction of saccharides with lipid bilayer vesicles: stabilization during freeze-thawing and freeze-drying. Biochim. Biophys. Acta 858(1), 169-180 (1986).
118. Chougule M, Padhi B, Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int. J. Nanomedicine 2(4), 675-688 (2007).
119. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech. 6(3), E482-E486 (2005).
120. Joshi M, Misra A. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin. Exp. Pharmacol. Physiol. 30(3), 153-156 (2003).
121. Codrons V, Vanderbist F, Ucakar B, Preat V, Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 93(5), 1241-1252 (2004).
122. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug Target. 16(9), 639-648 (2008).
123. Rooney S. Phospholipid composition, biosynthesis and secretion. In: Comparative Biology of the Human Lung. Parent RA (Ed.). CRC Press, FL, USA, 1, 511-544 (1992).
124. Schreier H. Liposome aerosols. J. Liposome Res. 2(2), 145-184 (1992).
125. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic efectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56, 600-612 (2003).
126. Schreier H, McNicol KJ, Ausborn M et al. Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. Int. J. Pharm. 87(1-3), 183-193 (1992).
127. Insmed company website describing Arikace for use in cystic fibrosis. www.insmed.com/product-candidates/arikace-for-cf-patients-with-pseudomonas-lung- infections (Accessed 4 June 2013)
128. Insmed company website describing Arikace for use in NTM. www.insmed.com/product-candidates/arikace-for-patients-with-ntm-lung-infections (Accessed 4 June 2013)
129. Study to evaluate Arikace™ in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, #NCT01315678. www.clinicaltrials.gov (Accessed 4 June 2013)